Push/Pull Archives • Page 2 of 3 • AMR.Solutions

WHO-FAO-OIE-UNEP survey on a multi-stakeholder AMR platform

Dear All (this newsletter experiments with an Executive Summary/Details format; let me know what you think), (Executive Summary) As a further support for implementation of recommendations from the UN Interagency Coordination Group on Antimicrobial Resistance (IACG AMR), the Tripartite Plus (WHO-FAO-OIE-UNEP) are seeking to create a Partnership Platform that will “engage institutions representing states, markets and

25 August 2021 No Comments

“Astonishing mismatch”: Market potential of AMR tools vs. patient needs

Dear All, We have today an excellent report from the Global AMR R&D Hub entitled “Estimating Global Patient Needs and Market Potential for Priority Health Technologies Addressing Antimicrobial Resistance.” Both the bottom line and the key message of the report are clearly stated in the Preface: “… we hope that by showing the astonishing mismatch

20 August 2021 No Comments

Pull incentives for antibiotics: How much and why? — A literature survey

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), The recent discussions of the NICE/NHS England pilot subscription model (detailed newsletter plus follow-up FAQ newsletter) and a new paper by Chantal Morel and colleagues on the idea of an Antibiotic Susceptibility Bonus (ASB, link) bring to the fore the question of how to value any given

14 April 2020 No Comments

UK Antibiotic Subscription Pilot implies Pull Incentive of up to $4b across the G20

Note that there is a follow-up newsletter that covers a post-webinar FAQ. After reading this newsletter as introduction, please go here for the follow-up newsletter. Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Prior newsletters have covered the antibiotic evaluation procurement pilot being run by NICE and NHS England (go here for the

29 March 2020 No Comments

Pull incentives in the EU / Statements by Commissioner Kyriakides

Dear All (and note the related 28 Nov 2020 newsletter), Stella Kyriakides, the European Commissioner for Health and Food Safety, made some really interesting statements before the European Parliament’s health committee (ENVI) on Thursday of last week (22 April). Per this Exchange of Views on the EP’s multimedia center and this news report, here are some

29 April 2021 No Comments

PASTEUR Act (re)introduced: A delinked Pull award advances in the US!

Dear All (with thanks to Kevin Outterson for leading this note), HUGE news today: Senator Michael F. Bennet and Senator Todd Young have introduced an updated PASTEUR Act that (if enacted) would create a predictable path to rewarding new #FireExtinguishersOfMedicine for their value to society via a subscription contract (valued at $750m to $3b) that prepays

30 September 2020 No Comments

AMR Action Fund: A $1b down payment from Industry; A call for creation of strong Pull incentives

“The world is changed by your example, not by your opinion” (Paulo Coelho) Dear All, The AMR Action Fund (https://www.amractionfund.com/) announcement today was awesome … indeed, it brought tears to my eyes. I listened in parallel to the presentations from Berlin and Washington where we had an all-star cast of US Senators, EU Members of

9 July 2020 No Comments

G20 Health Minister’s declaration / Calls for push, pull, avoiding price/volume mechanisms, and support of global partnerships!

Dear All: Adding to the continued forward momentum of calls for support of antibiotic R&D, this week’s meeting of the G20 Health Ministers has led to the attached declaration. After some very sound recitations of the importance of health communities and the importance of good infrastructure, we also have calls for R&D preparedness (Para 15), workforce building (Para 22),

20 May 2017 No Comments

Ardal et al. / Pull incentives for antibiotics – TATFAR analysis of 6 models

Dear All: The TATFAR group has a new and very helpful paper out in Clinical Infectious Diseases in which they analyze 6 different kinds of pull incentives: Higher reimbursement Diagnosis confirmation (lower cost for a few days of empiric therapy, higher cost if diagnostics confirm ongoing need) A fully delinked market entry reward (no sales-based income) A

8 June 2017 No Comments

Pull incentives for antibiotics: Duke-Margolis PAVE policy paper and PBS Newshour segments

Dear All: We can’t say it too often … our current approach to buying antibiotics is broken in that it is tantamount to paying the firemen on a per-fire basis. We simply must change this! Driving this change requires persistent effort on the part of many. Over the past few days we’ve had two welcome additions to

6 August 2017 No Comments

AMR.Solutions

Push/Pull